CClinicalTrials.gg
Sign In
CompletedNCT06717269Updated Jul 28, 2026

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

A Phase 1 interventional study of NX-5948 and Esomeprazole in Healthy Volunteer, sponsored by Nurix Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Nurix Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
223
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This is a multiple part, multiple cohort study evaluating single and multiple ascending doses, relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Nurix Therapeutics, Inc. is the lead sponsor of 10 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy, adult, male or female 19-55 years of age
  • Continuous non-smoker who has not used nicotine and tobacco-containing products for at least 3 months prior to the first dosing
  • Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2
  • Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, or vital signs at the screening visit, as deemed by the Principal Investigator (PI) or designee
  • Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol.

Key Exclusion Criteria:

  • Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
  • Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neoplastic myeloproliferative, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders
  • History of any gastrointestinal surgery or cholecystectomy that could impact the PK of NX-5948
  • History or presence of alcohol or drug abuse within the past 2 years
  • History or presence of hypersensitivity, angioedema, or idiosyncratic reaction to the study drug(s) or related compounds

  • History or presence of:

    • Significant multiple and/or severe allergies, including anaphylactic reaction.
    • Personal or family history of prolonged QT syndrome or family history of sudden cardiac death.
    • Evidence of atrial fibrillation, atrial flutter, complete bundle branch block, Wolff Parkinson-White Syndrome, or cardiac pacemaker.
    • Adrenal insufficiency.
    • Skin infection.
  • Female volunteers of childbearing potential
  • Female volunteer with a positive pregnancy test
  • Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at the screening visit
  • Donation of blood or significant blood loss within 56 days prior to the first dosing
  • Plasma donation within 7 days prior to the first dosing
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • Previous exposure to NX-5948.
  • Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    NX-5948 tablet and capsule under fasting and fed conditions; with and without placebo

    Drug: NX-5948 · Drug: Placebo

  • Experimental
    NX-5948 tablet and capsule with and without esomeprazole under fasting and fed conditions

    Drug: NX-5948 · Drug: Esomeprazole

  • Experimental
    NX-5948 with and without famotidine under fasting and fed conditions

    Drug: Famotidine · Drug: NX-5948

  • Experimental
    Midazolam with and without NX-5948

    Drug: Midazolam · Drug: NX-5948

  • Experimental
    Digoxin with and without NX-5948

    Drug: Digoxin · Drug: NX-5948

  • Experimental
    Rosuvastatin with and without NX-5948

    Drug: Rosuvastatin · Drug: NX-5948

  • Experimental
    NX-5948 with and without quinidine

    Drug: Quinidine · Drug: NX-5948

Interventions

  • DrugNX-5948

    Administered orally in tablet or capsule form

    Also known as: Bexobrutideg

  • DrugEsomeprazole

    Administered orally in capsule form

  • DrugPlacebo

    Administered orally matching NX-5948 tablets

  • DrugFamotidine

    Administered orally in tablet form

  • DrugMidazolam

    Administered orally in syrup form

  • DrugDigoxin

    Administered orally in tablet form

  • DrugRosuvastatin

    Administered orally in tablet form

  • DrugQuinidine

    Administered orally in tablet form

  • DrugNX-5948

    Administered in capsule form

    Also known as: Bexobrutideg

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948

    NX-5948 administered as a tablet or capsule under fasting and fed conditions; with and without esomeprazole, famotidine, or quinidine

    Time frame: 9 weeks

  2. Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf): NX-5948

    NX-5948 administered as a tablet or capsule under fasting and fed conditions; with and without esomeprazole, famotidine, or quinidine

    Time frame: 9 weeks

  3. Maximum observed concentration (Cmax): NX-5948

    NX-5948 administered as a tablet or capsule under fasting and fed conditions; with and without esomeprazole, famotidine, or quinidine

    Time frame: 9 weeks

  4. AUC0-t: Midazolam, rosuvastatin, or digoxin

    Midazolam, rosuvastatin, or digoxin administered with and without NX-5948

    Time frame: 9 weeks

  5. AUC0-inf: Midazolam, rosuvastatin, or digoxin

    Midazolam, rosuvastatin, or digoxin administered with and without NX-5948

    Time frame: 9 weeks

  6. Cmax: Midazolam, rosuvastatin, or digoxin

    Midazolam, rosuvastatin, or digoxin administered with and without NX-5948

    Time frame: 9 weeks

  7. Placebo-corrected change from baseline QT interval (QTc) as measured by electrocardiogram

    Time frame: Baseline, 9 weeks

  8. Number of participants with treatment-emergent adverse events

    Time frame: Up to 10 weeks

07

Study locations

2 sites
  • Celerion
    Phoenix, Arizona 85283, United States
  • Celerion
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06717269
Lead sponsor
Nurix Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Nov 30, 2024
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
Jul 28, 2026

Study contacts

Study Director
study director · Nurix Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Nurix Therapeutics, Inc.

Start the discussion